Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Gap Rebates Boost Medicare Rx Spending To 9% Gain In 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug spending by the Medicare program increased more than by Medicaid or by private payers in 2010, according to an analysis by CMS; expenditures in Medicaid and by private insurance were level with the previous year and consumer out-of-pocket spending declined. Total drug spending across-the-board rose 1.2% to $259 billion.

You may also be interested in...



Reimbursement News, In Brief

Updates on Medicare’s ACO program, drug spending trends and Medicare coverage of IVIG.

Donut Hole Discounts Would Cost Medicare $17.4 Bil.; AARP Wants Phase Out

The pharmaceutical industry proposal to provide 50 percent discounts on the price of branded drugs for Medicare Part D beneficiaries in the donut hole would wind up costing the federal government $17.4 billion over 10 years, according to estimates by the Congressional Budget Office and the Joint Committee on Taxation released Sept. 16

Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests

Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel